Sprout Health: What the FDA Letter Means for What You Pay

This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://joinsprouthealth.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.

1. 1

   “The following claim concerning compounded semaglutide and tirzepatide products appears on your website: "GLP-1 medications are FDA-approved and backed by extensive clinical research…."”

2. 2

   “Compounded drug products are not FDA-approved. Your claim implies that your products are the same as an FDA-approved product when they are not. As a result, this claim is false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA.”

1. 1

   Letter issued

   September 2025

2. 2

   15-working-day response window

   FDA gives the company 15 working days to respond in writing.

3. 3

   Close-out, if issued

   FDA may post one once it is satisfied the cited issues have been corrected.

joinsprouthealth.com returned a live storefront when we checked in August 2026, offering weight loss and an energy-and-longevity category and describing medication as prepared by state-licensed US pharmacies.

The sentence FDA objected to is one almost any weight-loss page could have written, and that is the point worth carrying away. Read on its own, "GLP-1 medications are FDA-approved" is a true statement about the drug class — Wegovy, Ozempic, Zepbound and Mounjaro are all approved. FDA's objection was to where the sentence sat: on a page selling compounded semaglutide and tirzepatide, which are not the approved products. Nothing here concerns what Sprout charges or whether the price is what it says it is. It concerns a general statement about a drug class doing work on a page about a specific product, and that is a pattern you will see on a lot of pricing pages once you know to look for it.

Doseworth’s review of Sprout Health has the pricing, the states served, and what’s included.

As of August 2026, FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence Sprout Health failed to respond.